Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

REDWOOD CITY, Calif. & BOSTON --(BUSINESS WIRE)--May 14, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024 . Details of the poster presentation are as follows: Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications Presenting Author: Yvan Chanthery , Ph.D. Date & Time: June 14, 2024 at 18:00 CEST About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20240514346504/en/ Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge [email protected] Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 [email protected] Source: Adicet Bio, Inc.

The release as fetched from its publisher. adicetbio.com ↗